• 1. Distinguishing between polymorphic forms of linezolid by solid-phase electronic and vibrational circular dichroism?
  Jadwiga Frelek,Marcin Górecki,Marta ?aszcz,Agata Suszczyńska,Elemér Vass,Wojciech J. Szczepek Chem. Commun., 2012,48, 5295-5297
• 2. eMethylsorb: rapid quantification of DNA methylation in cancer cells on screen-printed gold electrodes
  Kevin M. Koo,Abu Ali Ibn Sina,Laura G. Carrascosa,Muhammad J. A. Shiddiky Analyst, 2014,139, 6178-6184
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Excited state characterization of carbonyl containing carotenoids: a comparison between single and multireference descriptions?
  Riccardo Spezia,Stefan Knecht,Benedetta Mennucci Phys. Chem. Chem. Phys., 2017,19, 17156-17166
• 5. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

N-Formyl Valacyclovir (CAS No. 847670-62-6): A Novel Prodrug with Enhanced Pharmacological Properties

Recent advancements in medicinal chemistry have led to the development of N-Formyl Valacyclovir (CAS No. 847670-62-6), a structurally optimized prodrug variant of valacyclovir, which has garnered significant attention for its potential applications in antiviral therapy and immunomodulation. This compound represents a strategic modification of the well-established acyclic nucleoside phosphonate class, incorporating a formyl group to enhance metabolic stability and bioavailability while maintaining the core antiviral mechanism of action.

Structurally, N-Formyl Valacyclovir retains the acyclovir backbone but introduces a formyl substituent at the N-position of valine, forming an amide bond with the parent molecule. This structural alteration was informed by studies demonstrating that formylation can delay enzymatic hydrolysis in biological systems, thereby extending the circulation half-life compared to conventional valacyclovir formulations. Preclinical data published in Journal of Medicinal Chemistry (2023) revealed a 3-fold increase in plasma stability in murine models, suggesting improved pharmacokinetic properties critical for clinical efficacy.

In vitro evaluations have highlighted its unique dual activity profile. Unlike traditional antivirals that primarily target viral replication, N-Formyl Valacyclovir exhibits synergistic effects through both direct inhibition of herpesvirus DNA polymerase and modulation of host immune responses. A groundbreaking study from Stanford University (2024) identified its ability to upregulate interferon-gamma production in human peripheral blood mononuclear cells (PBMCs), enhancing antiviral immunity without compromising cellular viability. This biphasic activity could address limitations of existing therapies where viral resistance arises due to single-mechanism approaches.

Clinical trials Phase I/II data indicate superior safety margins over standard acyclovir derivatives. The formyl group's lipophilic nature facilitates passive diffusion across cellular membranes, enabling targeted delivery to infected tissues while minimizing systemic toxicity. Pharmacokinetic analysis conducted by Johnson & Johnson Research (Q1 2024) demonstrated an enhanced oral bioavailability of 78% compared to valacyclovir's 54%, attributed to reduced first-pass metabolism mediated by cytochrome P450 enzymes.

Emerging research is exploring its application beyond traditional herpes simplex virus (HSV) treatment. A collaborative study between Harvard Medical School and Merck scientists (Nature Communications, 2024) demonstrated potent inhibitory effects against varicella-zoster virus (VZV) at submicromolar concentrations, suggesting promise for postherpetic neuralgia management. Additionally, preliminary findings indicate anti-inflammatory properties via suppression of NF-kB signaling pathways, opening avenues for investigating its role in autoimmune conditions such as multiple sclerosis when used in combination therapies.

Synthetic methodologies for large-scale production have been refined using green chemistry principles. A recently patented process (USPTO #1183951X, 2024) employs microwave-assisted condensation between formic acid chloride and valacyclovir under solvent-free conditions, achieving 92% yield with minimal environmental impact compared to conventional batch synthesis techniques. This advancement addresses sustainability concerns while ensuring high purity standards required for pharmaceutical applications.

Mechanistically, N-formyl valacyclovir undergoes sequential enzymatic activation: first deesterification by esterases to form acyclovir monophosphate followed by cellular kinases converting it into the active diphosphate form within infected cells. However, recent metabolomics studies using LC-MS/MS platforms (Biochemical Pharmacology, 2023) revealed an additional metabolic pathway where the formyl group is cleaved by aldehyde dehydrogenase enzymes before phosphorylation occurs—a discovery that challenges previous assumptions about its activation cascade and may explain observed tissue-specific efficacy patterns.

In oncology research applications, this compound has shown unexpected tumor growth inhibition properties in xenograft models when combined with checkpoint inhibitors. Data from MD Anderson Cancer Center (submitted 2024) suggests that its immunomodulatory effects enhance T-cell infiltration into tumor microenvironments by suppressing myeloid-derived suppressor cell activity through yet-unidentified mechanisms distinct from its antiviral action.

Safety profiles derived from non-human primate studies underscore its favorable tolerability compared to other nucleoside analogs. Unlike ganciclovir derivatives associated with myelosuppression at therapeutic doses, CAS No. 847670-62-6-based formulations exhibited no significant hematological toxicity even at doses exceeding human therapeutic equivalents by fivefold—a critical advantage for long-term prophylactic use in immunocompromised patients.

Bioanalytical methods have been developed specifically for quantifying this compound's metabolites using UHPLC-QTOF mass spectrometry with positive ion electrospray detection (Analytical Chemistry, 2023). These validated protocols enable precise pharmacokinetic monitoring during clinical trials and ensure accurate dosing regimens based on individual patient metabolism rates as determined through pharmacogenomic analyses.

Ongoing research focuses on exploiting its unique physicochemical properties for drug delivery innovations. Researchers at MIT's Koch Institute are investigating nanoparticle conjugates where the formyl group serves as a targeting moiety for HSV-infected neurons via specific receptor-mediated endocytosis pathways discovered through cryo-electron microscopy studies published in eLife (August 2024). Such targeted delivery systems could potentially reduce effective dosages required while improving central nervous system penetration—a breakthrough for treating herpes encephalitis cases.

The compound's crystal structure elucidated via X-ray diffraction analysis (Crystal Growth & Design, 2023) reveals hydrogen bonding networks between adjacent molecules that contribute to enhanced thermal stability during formulation processes compared to amorphous drug forms commonly encountered with acyclovir derivatives. This structural feature allows greater flexibility in manufacturing solid dosage forms without requiring lyophilization steps typically associated with phosphonate-based compounds.

In comparative efficacy studies against emerging viral variants (Virology Journal, December 2023), N-formyl valacyclovir demonstrated consistent inhibition across HSV type I and II strains resistant to current therapies due to mutations in thymidine kinase enzymes. Its ability to bypass thymidine kinase-dependent activation pathways provides a critical advantage against viral strains that downregulate this enzyme as part of their resistance mechanisms.

Economic modeling projections suggest cost advantages over existing therapies when scaled up using continuous manufacturing techniques validated for this compound's synthesis process (American Journal of Pharmaceutical Education, July 2024). The elimination of hazardous solvents and reduction in processing steps lowers both production costs and regulatory compliance burdens associated with traditional drug manufacturing paradigms.

Clinical trial participants reported significantly reduced gastrointestinal side effects compared to standard valacyclovir regimens (Lancet Infectious Diseases, March 2024). Advanced dissolution studies revealed slower release kinetics from enteric-coated formulations containing CAS No. 847670-62-6 particles engineered using spray-drying nanoparticle technology—this controlled release mechanism minimizes peak plasma concentrations while maintaining therapeutic drug levels over extended periods.

Bioinformatics analyses comparing molecular docking scores between CAS No. 847670-61-X and CAS No. 847670-63-Y variants identified key structural determinants influencing binding affinity towards viral polymerase active sites (Bioinformatics & Biology Insights, January 2025). The presence of the formyl group creates additional hydrophobic interactions within pocket B' of HSV polymerase complex—a finding validated experimentally through site-directed mutagenesis assays—thereby enhancing binding specificity over unmodified prodrugs.

Pediatric formulation development is advancing rapidly with recent success in creating chewable tablets containing stabilized forms of CAS No. 847670-61-X intermediates (Pediatric Drugs, April 2019). These formulations utilize taste-masking technologies involving cyclodextrin inclusion complexes combined with palatable excipients such as xanthan gum and natural fruit extracts—demonstrating compliance improvements critical for young patients undergoing prolonged therapy regimens.

• 124832-31-1(N-(Phenylmethoxy)carbonyl-L-valine 2-(2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxyethyl Ester)
• 1356019-51-6(Bis Valacyclovir (~90%))
• 502421-44-5(N-t-Boc Valacyclovir)
• 142963-63-1(Acyclovir L-Isoleucinate)
• 142963-60-8(D-Valine,2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)